Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
98
-
Total 13F shares, excl. options
-
26.1M
-
Shares change
-
-357K
-
Total reported value, excl. options
-
$886M
-
Value change
-
-$1.16M
-
Number of buys
-
58
-
Number of sells
-
-49
-
Price
-
$33.80
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q2 2021
130 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2021.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 98 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.1M shares
of 45.1M outstanding shares and own 57.91% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.45M shares), BlackRock Inc. (2.7M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (1.64M shares), FMR LLC (1.55M shares), STATE STREET CORP (1.39M shares), ALLIANCEBERNSTEIN L.P. (1.35M shares), Artisan Partners Limited Partnership (1.32M shares), First Light Asset Management, LLC (950K shares), and GOLDMAN SACHS GROUP INC (820K shares).
This table shows the top 98 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.